All In Biotech

Drug Trial Radar · NCT06663358

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Last checked: Nov 20, 2026Latest source record: Nov 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 6, 2024

Primary completion

Nov 2029

Study completion Nov 2029

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.

Conditions

  • Fabry Disease

Interventions

  • Pegunigalsidase-alfaDrug

    Administered via intravenous (IV) infusion under conditions of routine clinical care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Glomerular Filtration Rate (eGFR)Time frame: 4 years
  2. Plasma Globotriaosylsphingosine (LysoGb3) ConcentrationTime frame: 4 years
  3. Left Ventricular Mass Index (LVMI; g/m2)Time frame: 4 years
  4. High Sensitivity Troponin (hs-cTnT)Time frame: 4 years
  5. Safety AssessmentsTime frame: 4 years

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Infusion Associates

    Grand Rapids, Michigan · Recruiting

  • Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC)

    Fairfax, Virginia · Recruiting

  • General Hospital Slovenj Gradec

    Slovenj Gradec, Slovenia · Recruiting

  • The Royal Free Hospital

    London, United Kingdom · Recruiting

  • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital

    Edgbaston, Birmingham, United Kingdom · Recruiting

  • Salford Royal

    Salford, Greater Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.